Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.
Symbol:
Current Quote
last: 0.42
bid:
ask:
volume: 21300

as of (GMT): 2012-07-02 16:00:00
*Quotes delayed by 20min.
Stock Exchange / Market : [ n/a ]
 Listed 5 consecutive market days. On list 02/06/2012 through 02/13/2012 

3 Month
MSHL 3 Month

6 Month
MSHL 6 Month

1 Year
MSHL 1 Year

Borrow Rates (per share)